TipRanks
Bausch + Lomb Corporation (DE:S2L)
FRANKFURT:S2L
Germany Market
S2L
Bausch + Lomb Corporation
RESEARCH TOOLSreports

Bausch + Lomb Corporation (S2L) Stock News & Sentiment

1 Followers
Bausch + Lomb Prepares Oral Dry AMD Drug Candidate for Clinical Launch in 2027
Premium
Company Announcements
Bausch + Lomb Prepares Oral Dry AMD Drug Candidate for Clinical Launch in 2027
1d ago
BLCO
Bausch + Lomb Sets Date for Third-Quarter 2026 Earnings Release and Investor Call
Premium
Company Announcements
Bausch + Lomb Sets Date for Third-Quarter 2026 Earnings Release and Investor Call
3d ago
BLCO
Yi Chen Reiterates Buy on Bausch + Lomb, Citing Emerging Ophthalmology Pipeline and Maintaining $21 Price Target
Premium
Ratings
Yi Chen Reiterates Buy on Bausch + Lomb, Citing Emerging Ophthalmology Pipeline and Maintaining $21 Price Target
1M ago
BLCO
Bausch + Lomb Overhauls Board, Reaffirms 2026 Outlook
Premium
Company Announcements
Bausch + Lomb Overhauls Board, Reaffirms 2026 Outlook
2M ago
8K
BLCO
Bausch + Lomb Earnings Call Signals Growing Momentum
Premium
Company Announcements
Bausch + Lomb Earnings Call Signals Growing Momentum
2M ago
BLCO
Bausch + Lomb Shareholders Back Board and Executive Pay
Premium
Company Announcements
Bausch + Lomb Shareholders Back Board and Executive Pay
5M ago
8K
BLCO
Bausch + Lomb Lifts Outlook After Margin-Heavy Quarter
Premium
Company Announcements
Bausch + Lomb Lifts Outlook After Margin-Heavy Quarter
5M ago
BLCO
More DE:S2L News >

S2L News on the Web

Barclays Reaffirms Their Buy Rating on Bausch + Lomb Corporation (BLCO)
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Thermo Fisher (TMO), Bausch + Lomb Corporation (BLCO) and DaVita (DVA)
TipRanks News
Bullish
Yi Chen Reiterates Buy on Bausch + Lomb, Citing Emerging Ophthalmology Pipeline and Maintaining $21 Price Target
TipRanks News
Bullish
Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA)
TipRanks News
Neutral
Bausch + Lomb (BLCO) Halts Development of Glaucoma Eye Drop After Phase 2 Study
GuruFocus News
Bearish
Bausch + Lomb says Phase 2 study of BL1107 did not achieve primary endpoint
TipRanks News
Bearish
Bausch + Lomb Falls Despite Bullish Citi Target Hike
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
DE:S2L
Sector Average
Media Buzz
This Week9 articles
Weekly Average2 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:S2L’s Media Buzz Sentiment?
9 articles about DE:S2L were published this week. In an average week, 2 articles are published.
    What is DE:S2L’s weekly average amount of articles?
    In an average week, 2 articles about DE:S2L are published.
      What is DE:S2L’s News Sentiment?
      100% of articles about DE:S2L were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        XENEXenon
        ABTAbbott Laboratories
        BBIOBridgeBio Pharma
        BDXBecton Dickinson
        NVSNovartis
        Showing the stocks with the most bullish news sentiment over the past week